ArticleCell & bioscience2025
ZMIZ2 interacts with PIN1 to promote lung adenocarcinoma EMT and metastasis via activation of the PI3K/AKT pathway.
Article in Cell & bioscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
ZMIZ2, a transcription co-activator, is frequently overexpressed in various tumors. However, its functional role and molecular mechanisms in driving non-small cell lung cancer (NSCLC) metastasis remain elusive. Our study reveals that ZMIZ2 is significantly overexpressed in lung adenocarcinoma (LUAD) tissues and is strongly correlated with adverse patient outcomes. Elevated ZMIZ2 expression enhances LUAD cell proliferation, migration, invasion and metastasis, whereas ZMIZ2 depletion exerts opposing effects. Mechanistically, ZMIZ2 physically interacts with PIN1 to trigger K63-linked ubiquitination-dependent PIN1 stabilization, which consequently hyperactivates the PI3K/AKT signaling axis. Notably, silencing PIN1 expression significantly attenuated ZMIZ2-mediated activation of the PI3K/AKT signaling pathway and inhibited LUAD cell proliferation, migration and invasion. Collectively, our findings establish ZMIZ2 as a novel metastasis driver that orchestrates LUAD progression through PIN1-mediated PI3K/AKT pathway activation, providing a rationale for targeting this axis in precision oncology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.